1. Protein Tyrosine Kinase/RTK
  2. Ephrin Receptor
  3. ALW-II-41-27

ALW-II-41-27 (Synonyms: Eph receptor tyrosine kinase inhibitor)

Cat. No.: HY-18007 Purity: 99.38%
Handling Instructions

ALW-II-41-27 is a Eph family tyrosine kinase inhibitor with an IC50 of 11 nM for Eph2.

For research use only. We do not sell to patients.

ALW-II-41-27 Chemical Structure

ALW-II-41-27 Chemical Structure

CAS No. : 1186206-79-0

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 281 In-stock
Estimated Time of Arrival: December 31
5 mg USD 210 In-stock
Estimated Time of Arrival: December 31
10 mg USD 330 In-stock
Estimated Time of Arrival: December 31
50 mg USD 990 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 17 publication(s) in Google Scholar

Top Publications Citing Use of Products

    ALW-II-41-27 purchased from MCE. Usage Cited in: Oncogene. 2017 Oct 5;36(40):5620-5630.

    C3-TAg cells are starved and stimulated for 0, 15 and 30 min with ephrin-A1-Fc (EphA2 ligand; 1 μg/mL) in the presence or absence of ALW-II-41-27 or NG-25 control. EphA2 is immunoprecipitated and products probed for tyrosine phosphorylation and EphA2. ALW-II-41-27 significantly reduces basal and ephrin-A1-Fc induced tyrosine phosphorylation.

    ALW-II-41-27 purchased from MCE. Usage Cited in: Nat Commun. 2017 Jun 6;8:15729.

    EphA2 immunoprecipitates prepared from MCF-7 cells expressing ectopic EphA2 are immunoblotted with anti-phosphotyrosine and anti-EphA2 antibody. The indicated samples are treated with recombinant human ephrin-A1 (500 ng/mL) for 20 min. Eight-hour pre-treatment with the EphA2 inhibitor ALW-II-41-27 (100 nM) suppressed ephrin-A1-induced EphA2 phosphorylation.

    ALW-II-41-27 purchased from MCE. Usage Cited in: Oncotarget. 2017 Nov 1;8(61):104330-104346.

    MC38-CT or -CC1-L cells are treated with 1 μM of DMSO, or the non-specific NG-25 or specific ALW-II-41-27 EPHA2 receptor inhibitor for indicated periods of time, followed by stimulation with EFNA1-Fc (2 μg/mL) in the last 15 min of treatments. Protein lysates are prepared and subjected to immunoblotting using antibodies to determine the effect of kinase inhibitors on EPHA2 activation.

    ALW-II-41-27 purchased from MCE. Usage Cited in: Front Pharmacol. 2018 Mar 27;9:272.

    ALW-II-41-27 activates Nrf2 signaling whereas inhibits NF-kB signaling in Trichinella spiralis-infected mice.

    ALW-II-41-27 purchased from MCE. Usage Cited in: J Cancer Res Clin Oncol. 2018 Sep;144(9):1649-1663.

    Western blot analysis of E-cadherin, Cytokeratin, N-cadherin and Snail in AGS cells treated with 1 µM of ALW-II-41-27.

    ALW-II-41-27 purchased from MCE. Usage Cited in: FASEB J. 2019 Apr;33(4):5495-5509.

    Western analysis of p-EPHA2, EPAH2, p-AKT, AKT, P-ERK, ERK protein expression in the treatment of ALW-II-41-27 or transfected with siEPHA2 in GM before myogenic differentiation.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    ALW-II-41-27 is a Eph family tyrosine kinase inhibitor with an IC50 of 11 nM for Eph2.

    IC50 & Target

    IC50: 11 nM (Eph2)[1]

    In Vitro

    ALW-II-41-27 inhibits Ba/F3 cells transformed with Tel fusions of EphA3, Kit, Fms, KDR, FLT1, FGR, Src, Lyn, Bmx, and Bcr-Abl with an EC50 below 500 nM. ALW-II-41-27 exhibits cross reactivity with Bcr-Abl. ALW-II-41-27 inhibits b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2, EphB3, Frk, Kit, Lck, p38α, p38β, PDGFRα, PDGFRβ, and Raf1 and many more demonstrating how introduction of the thiophene group can have a tremendous impact on kinase selectivity[1].

    Molecular Weight

    607.69

    Formula

    C₃₂H₃₂F₃N₅O₂S

    CAS No.

    1186206-79-0

    SMILES

    CC1=C(NC(C2=CC(C3=CC=CS3)=CN=C2)=O)C=C(C(NC4=CC=C(CN5CCN(CC)CC5)C(C(F)(F)F)=C4)=O)C=C1

    Shipping

    Room temperature in continental US; may vary elsewhere

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 47 mg/mL (77.34 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.6456 mL 8.2279 mL 16.4558 mL
    5 mM 0.3291 mL 1.6456 mL 3.2912 mL
    10 mM 0.1646 mL 0.8228 mL 1.6456 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      ALW-II-41-27 is prepared in 10% 1-methyl-2-pyrrolidinone and 90% polyethylene glycol 300[2].

    References

    Purity: 99.38%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    ALW-II-41-27
    Cat. No.:
    HY-18007
    Quantity: